201 related articles for article (PubMed ID: 35922667)
1. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β
Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y
Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
[TBL] [Abstract][Full Text] [Related]
3. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
5. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic base editing of human hematopoietic stem cells.
Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
[TBL] [Abstract][Full Text] [Related]
7. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
10. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
[TBL] [Abstract][Full Text] [Related]
11. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
12. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
Mahmoud Ahmed NH; Lai MI
Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
[TBL] [Abstract][Full Text] [Related]
15. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
Elife; 2022 Feb; 11():. PubMed ID: 35147495
[TBL] [Abstract][Full Text] [Related]
17. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.
Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM
Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654
[TBL] [Abstract][Full Text] [Related]
18. Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.
Ajami M; Atashi A; Kaviani S; Kiani J; Soleimani M
J Cell Biochem; 2020 Feb; 121(2):1420-1430. PubMed ID: 31596028
[TBL] [Abstract][Full Text] [Related]
19. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
[TBL] [Abstract][Full Text] [Related]
20. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
